Inhibition of CD4+CD25 + regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Lee IV, Major K ^a   Xu, Shuwen ^a   Fitzpatrick, Elizabeth H ^a   Sharma, Anupama ^a   Graves, Holly L ^a   Czerniecki, Brian J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVATION; DRUG MECHANISM; EFFECTOR CELL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TRANSCRIPTION REGULATION; UPREGULATION;

CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LIPOPOLYSACCHARIDES; MALE; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84892930743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074698     Document Type: Article

References (38)

1. Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287.
2. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
3. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296.
4. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227: 221-233.
5. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
6. Porrett PM, Yuan X, LaRosa DF, Walsh PT, Yang J, et al. (2008) Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 181: 1692-1699.
7. LaRosa DF, Gelman AE, Rahman AH, Zhang J, Turka LA, et al. (2007) CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett 108: 183-188.
8. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, et al. (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309: 1380-1384.
9. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
10. Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, et al. (2006) Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116: 485-494.
11. Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, et al. (2009) Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25- dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 119: 387-398.
12. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ (2008) Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev 222: 256-276.
13. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, et al. (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67: 1842-1852.
14. Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, et al. (1997) Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol 159: 3823-3837.
15. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171: 131-137.
16. Porrett PM, Lee MK, Lian MM, Wang J, Caton AJ, et al. (2008) A direct comparison of rejection by CD8 and CD4 T cells in a transgenic model of allotransplantation. Arch Immunol Ther Exp (Warsz) 56: 193-200.
17. Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, et al. (2008) Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol 86: 650-658.
18. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, et al. (2003) Rapid high efficiency sensitization of CD8 + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 171: 2251-2261.
19. Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, et al. (2008) Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol 181: 3137-3147.
20. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, et al. (2009) IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 183: 2475-2483.
21. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, et al. (2009) IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113: 4240-4249.
22. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, et al. (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113: 6102-6111.
23. Brinster C, Shevach EM (2005) Bone marrow-derived dendritic cells reverse the anergic state of CD4+CD25+ T cells without reversing their suppressive function. J Immunol 175: 7332-7340.
24. Klein L, Khazaie K, von Boehmer H (2003) In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 100: 8886-8891.
25. Koenecke C, Lee CW, Thamm K, Fohse L, Schafferus M, et al. (2012) IFN-gamma production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J Immunol 189: 2890-2896.
26. Cope A, Le Friec G, Cardone J, Kemper C (2011) The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. Trends Immunol 32: 278-286.
27. North RJ, Bursuker I (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-122+ effector T cells. J Exp Med 159: 1295-1311.
28. Delluc S, Hachem P, Rusakiewicz S, Gaston A, Marchiol-Fournigault C, et al. (2009) Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother 58: 1669-1677.
29. Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, et al. (2009) Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep 22: 337-343.
30. Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174: 99-106.
31. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
32. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
33. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, et al. (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782.
34. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633.
35. Eggermont AM (2009) Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 15: 6745-6747.
36. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, et al. (2009) The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 69: 4335-4345.
37. LaCelle MG, Jensen SM, Fox BA (2009) Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 15: 6881-6890.
38. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM (2006) Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108: 2655-2661.